Sorafenib is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC).
Sorafenib is indicated for the treatment of patients with advanced renal cell carcinoma (RCC).
Sorafenib is indicated for the treatment of patients with locally recurrent or metastatic, progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine therapy.
Indicated for the treatment of unresectable hepatocellular carcinoma, advanced r···【more】
Release date:2026-10-21Recommended:2